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Continuous venovenous hemodialysis treatment in critically ill ual fluid removal [3]. It is unclear, however, whether
patients after liver transplantation. these advantages result in an improved outcome. In a
Background. Acute renal failure (ARF) in critically ill pa- recent series, the outcome of patients with ARF appearstients is associated with a high mortality rate. Continuous renal
to be only modestly better than two or more decadesreplacement therapy (CRRT) is now widely used for the treat-
ago [4]. However, in most studies, patients with ARFment of ARF in these critically ill patients. We retrospectively
analyzed the role of CRRT as a prognostic parameter in pa- represent a heterogeneous patient group with different
tients receiving a cadaveric liver graft in 1998. underlying diseases. Thus, the interpretation of these
Methods. We reviewed the patient records of all adult recipi- reports is difficult.ents of a cadaveric liver graft (N 5 54) in 1998 and compared
Patients with an advanced liver disease frequently suf-those who underwent CRRT treatment (N 5 19) to those
fer from a reduced renal function [5]. This may resultwithout CRRT treatment (N 5 35).
Results. Mortality was high in the continuous venovenous from common pathomechanisms such as infections or
hemodialysis (CVVHD) group (58%). At the time of trans- toxic effects that affect both organs or from secondary
plantation, creatinine (1.7 6 0.4 vs. 1.0 6 0.1 mg/dl), blood urea renal failure as a consequence of hepatic dysfunction,nitrogen (40 6 13 vs. 22 6 3 mg/dl), aspartate aminotransferase
that is, the hepatorenal syndrome. Therefore, we retro-(ASAT; 585 6 420 vs. 242 6 97 U/liter), and bilirubin (11.6 6
spectively analyzed our data regarding perioperative4.1 vs. 6.5 6 1.9 mg/dl) were higher in the CVVHD group than
in controls, whereas hemoglobin (10.3 6 0.6 vs. 10.8 6 0.4 g/dl), continuous venovenous hemodialysis (CVVHD) treat-
white blood cells (6.3 6 0.6 vs. 7.0 6 0.8/nl), and thrombocytes ment in liver-graft recipients. In these patients with a
(110 6 18 vs. 90 6 10/nl) were similar. After transplantation, relatively small number of underlying diseases, ARF isliver graft function was impaired in the CVVHD group as
common with liver transplantation as a clearly definedcompared with controls.
start point of injury.Conclusions. The necessity for CRRT in patients after liver
transplantation correlates with a high risk of death. Thus, more
efforts have to be made to prevent renal failure in patients
after liver transplantation. METHODS
All records from patients in our hospital who were
undergoing cadaveric liver transplantation between Jan-
Acute renal failure (ARF) in critically ill patients is uary 1, 1998, and December 31, 1998, were retrospec-
often associated with multiorgan dysfunction as well as tively examined and followed for three months after
a high mortality rate [1]. Continuous renal replacement transplantation. Pretransplant and peritransplant vari-
therapy (CRRT) is used with increasing frequency in ables (age, sex, body mass index, underlying disease,
the management of critically ill patients with ARF [2]. warm and cold ischemic time) were recorded, and clinical
The modalities used are arteriovenous or venovenous as well as laboratory data, including immunosuppressive
hemofiltration or hemodialysis. These techniques are trough levels (monoclonal TDX Abbot Assay), were
preferred with respect to intermittent hemodialysis in monitored daily for up to 14 days after transplantation.
critically ill patients, as they are associated with a higher Furthermore, patient deaths were evaluated during the
hemodynamic stability and allow a continuous and grad-
entire follow-up period. Patients with CRRT were com-
pared with those without. Variables were analyzed ac-
cording to their impact on mortality.Key words: liver transplant, continuous renal replacement therapy,
acute renal failure, critical care medicine. Dialysis support was initiated using Fresenius ADM08
(Bad Homburg, Germany) and Hospal BSM-22 (Lyon, 1999 by the International Society of Nephrology
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Table 1. Demographic data
CVVHD group Control group Significance
Included patients N 19 35 —
Age years 51.362.4 49.261.9 NS
Sex female/male 8/11 13/22 NS
Death N 11 4 ,0.01
Body mass index 22.6 60.6 24.260.6 NS
Cold ischemic time hours 9.161.4 6.260.5 NS
Second warm ischemic time minutes 42.163.4 46.163.8 NS
High urgency transplantation N 7 2 NS
Hospitalized before transplantation N 4 1 NS
Abbreviations are: CVVHD, continuous venovenous hemodialysis; N, number; NS, not significant.
Table 2. Clinical parameters at transplantation Continuous venovenous hemodialysis treatment was
initiated 7.1 6 2.0 days after transplantation (range 22CVVHD group Control group Significance
to 28 days). Two patients were already treated at theCreatinine mg/dl 1.760.4 1.060.1 NS
BUN mg/dl 40613 2263 NS time of transplantation. CVVHD treatment was per-
Hemoglobin g/dl 10.360.6 10.860.4 NS formed for 14.1 6 3.8 days (range 2 to 62 days). CVVHD
Leukocytes x/nl 6.360.6 7.060.8 NS
had to be reinitiated in 8 out of 19 patients (42%), whileThrombocytes x/nl 110618 90610 NS
Bilirubin mg/dl 11.664.1 6.561.9 NS a third course of CVVHD was necessary in one patient.
Total protein g/dl 6.660.3 6.060.2 NS A retransplantation was necessary five times in four pa-ASAT U/liter 5856420 242697 NS
tients of the CVVHD group. No patient of the control
group needed a retransplantation.
After transplantation, liver graft function, as indicated
by bilirubin and ASAT levels, was impaired in the
France) devices with bicarbonate-buffered solutions CVVHD group as compared with controls (Fig. 1). In the
(SH44-HEP; Schiwa, Glandorf, Germany). CRRT was course after transplantation, there were no remarkable
performed as CVVHD. Heparin was used for anticoagu- differences regarding the levels of hemoglobin, white
lation. blood cells, and thrombocytes (data not shown). There
Results are reported as the mean 6 sem. Data were were also no significant differences regarding immuno-
analyzed with the chi-square test and the Mann–Whitney suppression.
test for nonparametric data. Statistics were performed
using the Statistical Software Package (SPSS).
DISCUSSION
The necessity for CRRT in patients after liver trans-RESULTS
plantation correlates with a high risk of death, with mor-A total of 54 patients was included into the study.
tality rates as high as 50 to 90% [6, 7]. In this study, weNineteen patients were treated with CVVHD (CVVHD
retrospectively analyzed the role of CRRT in criticallygroup), and the remaining 35 patients served as controls.
ill patients after cadaveric liver transplantation in orderClinical data are presented in Table 1. In the CVVHD
to evaluate the relationship of CRRT to the outcome.group, 58% of the patients died (36.6 6 7.9 days after
Interventional studies in patients suffering from ARFtransplantation, 29.3 6 8.8 days after start of CRRT) as
on the ICU must face many problems [8]. In these pa-compared with 11% of the patients in the control group
tients, ARF is usually part of a multifactorial process in(10.8 6 4.3 days after transplantation; Table 1). This
that, although some of the causes are known, the precisedifference was statistically significant (P , 0.01).
mechanisms leading to renal failure are incompletelyThere were trends toward a lower body mass index
understood. In order to further understand the dilem-and a longer cold ischemic time of the graft in the
mas, the study population should be well defined withCVVHD group. In the CVVHD group, more patients
respect to the underlying diseases. In our setting, theawaited the transplantation on the intensive care unit
diagnostic spectrum was narrow and the time point of(21 vs. 3%) and were graded “high urgency” (37 vs. 5%).
injury was precisely defined because it was the liver trans-At the time of transplantation, creatinine, blood urea
plantation itself [9].nitrogen (BUN), aspartate aminotransferase (ASAT),
At the time point of transplantation, we found a trendand bilirubin were higher in the CVVHD group than in
toward a lower body mass index in the CVVHD group,controls, whereas hemoglobin, white blood cells, and
thrombocytes were similar (Table 2). indicating malnutrition and muscle wasting typical for
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fects renal function with a decline in the glomerular
filtration rate of 30 to 50% [5]. Cyclosporine trough
levels had no obvious influence on the need for CVVHD
treatment in our population. This result from our small
sample size precludes a relevant subgroup analysis. We
assume that other causes such as graft function dominate
the influence of immunosuppression during the perioper-
ative need for renal replacement therapy.
In our patients, liver and kidney function was impaired
in the CVVHD group before and after transplantation.
A poor kidney function could be the result of poor liver
function. Therefore, one of the major therapeutic goals
must be to optimize renal blood supply and to minimize
nephrotoxicity in the management of patients after liver
transplantation. Also, the most appropriate time to start
renal replacement therapy has not been defined. CRRT
may be more useful when started early in order to pre-
vent the development of ARF rather than to treat it
[2]. Therefore, a multidisciplinary approach to achieve
optimal care for critically ill patients with renal failure
after liver transplantation is needed.
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